Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

About two-thirds of people get goosebumps and the remaining one-third do not. While they don’t help humans much today, they ...

Jefferies raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $19 from $16 and keeps a Buy rating on the shares. The firm views ...

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Jefferies Financial Group from $16.00 to ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Arcutis Biotherapeutics, Inc. (ARQT) been one of those stocks ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...

Arcutis Biotherapeutics (ARQT) announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting, AAD. The ...

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional ...

WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical ...

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and ...

WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...